IRIS
CIMADAMORE, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.329
NA - Nord America 1.722
SA - Sud America 1.458
EU - Europa 1.197
AF - Africa 194
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 9.907
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 2.706
US - Stati Uniti d'America 1.614
BR - Brasile 1.159
CN - Cina 893
HK - Hong Kong 581
VN - Vietnam 506
IT - Italia 269
RU - Federazione Russa 227
FR - Francia 221
DE - Germania 210
KR - Corea 181
AR - Argentina 115
IN - India 98
TG - Togo 68
BD - Bangladesh 64
ID - Indonesia 58
MX - Messico 58
EC - Ecuador 57
GB - Regno Unito 57
IQ - Iraq 43
TR - Turchia 38
ZA - Sudafrica 36
AT - Austria 32
CO - Colombia 31
FI - Finlandia 29
PY - Paraguay 28
CL - Cile 26
NL - Olanda 26
CA - Canada 25
PL - Polonia 25
JP - Giappone 21
PK - Pakistan 20
ES - Italia 19
VE - Venezuela 18
UA - Ucraina 16
UZ - Uzbekistan 16
EG - Egitto 15
MA - Marocco 14
TN - Tunisia 14
IE - Irlanda 13
KE - Kenya 13
LT - Lituania 13
JO - Giordania 12
SA - Arabia Saudita 11
UY - Uruguay 11
PE - Perù 10
AE - Emirati Arabi Uniti 9
DZ - Algeria 9
SE - Svezia 9
AZ - Azerbaigian 8
KZ - Kazakistan 6
NP - Nepal 6
IL - Israele 5
LB - Libano 5
PH - Filippine 5
CZ - Repubblica Ceca 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
HN - Honduras 4
JM - Giamaica 4
SY - Repubblica araba siriana 4
AL - Albania 3
AM - Armenia 3
AO - Angola 3
BH - Bahrain 3
BO - Bolivia 3
GR - Grecia 3
IR - Iran 3
KW - Kuwait 3
MD - Moldavia 3
OM - Oman 3
QA - Qatar 3
SN - Senegal 3
TW - Taiwan 3
BE - Belgio 2
BW - Botswana 2
CR - Costa Rica 2
GT - Guatemala 2
HU - Ungheria 2
LK - Sri Lanka 2
LV - Lettonia 2
LY - Libia 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
PS - Palestinian Territory 2
PT - Portogallo 2
SV - El Salvador 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
AD - Andorra 1
AQ - Antartide 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BY - Bielorussia 1
CD - Congo 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CW - ???statistics.table.value.countryCode.CW??? 1
DJ - Gibuti 1
Totale 9.883
Salva come PNG Salva come JPEG
Città #
Singapore 719
Hong Kong 571
Beijing 371
Boardman 199
Lauterbourg 190
Hefei 183
Ho Chi Minh City 180
Seoul 178
Ashburn 172
Frankfurt am Main 148
Hanoi 122
San Jose 122
Los Angeles 100
Redondo Beach 91
São Paulo 91
Dallas 84
The Dalles 82
Buffalo 71
Lomé 68
Ogden 59
Rio de Janeiro 40
Council Bluffs 33
Milan 32
New York 32
Guayaquil 30
Nuremberg 28
Rome 28
Belo Horizonte 27
Mexico City 25
Brasília 24
Mumbai 23
Porto Alegre 23
Curitiba 21
Helsinki 20
Biên Hòa 19
Da Nang 18
Ispra 18
Boston 17
Haiphong 17
Hyderabad 17
Santa Clara 17
Warsaw 17
Naples 16
Orem 16
Tokyo 16
Vienna 16
Amsterdam 15
Campinas 14
Johannesburg 14
Ribeirão Preto 14
Salvador 14
Brooklyn 13
Codroipo 13
Quito 13
Tashkent 13
Baghdad 12
Chicago 12
Goiânia 12
Montreal 12
Thái Bình 12
Amman 11
Dublin 11
Jakarta 11
Maceió 11
Munich 11
Nairobi 11
Santo André 11
Shanghai 11
Ankara 10
Atlanta 10
Columbus 10
Denver 10
Duque de Caxias 10
Franca 10
Guangzhou 10
Hải Dương 10
Istanbul 10
Xi'an 10
Asunción 9
Cape Town 9
Carapicuíba 9
Fortaleza 9
Thái Nguyên 9
Tunis 9
Buenos Aires 8
Bắc Giang 8
Cabo Frio 8
Chennai 8
Dhaka 8
Guarulhos 8
London 8
Manaus 8
Medellín 8
Montevideo 8
Poplar 8
Baku 7
Bogotá 7
Caracas 7
Erbil 7
Jeddah 7
Totale 4.939
Salva come PNG Salva come JPEG
Nome #
News in the classification of WHO 2022 bladder tumors 165
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer 129
SIUrO best practice recommendations to optimize BRCA 1/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure: BOP) 103
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis 99
Novel Therapeutic Strategies for Metastatic Prostate Cancer Care 95
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer 80
A gender-related dichotomy in bladder cancer 79
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems 76
The uropathologist of the future: getting ready with intelligence for the prostate cancer tsunami 75
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 74
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 74
Giant cell carcinoma of the urinary bladder: Clinicopathologic analysis and oncological outcomes 73
Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis 70
Biological and therapeutic implications of FGFR alterations in urothelial cancer: A systematic review from non-muscle-invasive to metastatic disease 69
Conceptual Analogies Between Multi-Scale Feeding and Feedback Cycles in Supermassive Black Hole and Cancer Environments 68
How To Report the Minor Component of a High-grade Pattern in Radical Prostatectomy Specimens: Time To Abandon the “Tertiary” Terminology? 68
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 68
The Prognostic Significance of Histological Subtypes in Patients with Muscle-Invasive Bladder Cancer: An Overview of the Current Literature 66
Epigenetic modulations and lineage plasticity in advanced prostate cancer 66
Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review 66
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial 65
Agent-Based Learning Model for the Obesity Paradox in RCC 65
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 64
Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets 64
An update on investigational therapies that target STAT3 for the treatment of cancer 64
Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis 63
Histopathology of Prostate Cancer and its Precursors 63
Prognostic Significance of Programmed Cell Death-1, Programmed Cell Death-Ligand 1, Programmed Cell Death-Ligand 2, and Fibroblast Growth Factor Receptor 3 mRNA Expression in Bladder Cancer 63
Re: Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population 63
Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group 63
Targeted treatment of renal cell carcinoma 60
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 60
Are liver nested stromal epithelial tumors always low aggressive? 59
Treating prostate cancer by antibody-drug conjugates 59
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 59
PreImplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness 58
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A) 58
Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives 57
Patients ask and pathologists answer: ten questions around prostate cancer grading 57
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 57
Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder 57
Epigenetic modifications and modulators in prostate cancer 57
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 56
Bone targeting agents in patients with metastatic prostate cancer: State of the art 56
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 56
Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. J Vasc Interv Radiol 2018;29:589–97. Eur Urol 2018;74:525–6: Could Morphologic Changes in Periprostatic Arteries Have an Influence on Prostatic Artery Embolization? 56
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) 56
Re: George J. Netto, Mahul B. Amin, Eva M. Compérat, et al. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.015 55
Uropathologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance 55
Prostate cancer in 2021: Novelties in prognostic and therapeutic biomarker evaluation 55
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward 55
An update on immunotherapy in uro-oncology 55
PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming? 55
Digital real-time microscopy of ex-vivo tissues: A novel strategy to control surgical accuracy 54
Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One 54
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 54
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 54
Grading of Chromophobe Renal Cell Carcinoma: Do We Need It? 53
Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667–75: How Does Circulating DNA Reach the Blood Stream? 53
pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging 53
Staging and reporting of renal cell carcinomas 53
The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors 53
Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489–91 52
Spectrum of incipient (or precursor) lesions in the mucosa of the seminal vesicles 52
The most effective but largely ignored target for prostate cancer early detection and intervention 51
Designing novel immunocombinations in metastatic renal cell carcinoma 51
Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer 51
Quick steps toward precision medicine in renal cell carcinoma 51
T1 bladder carcinoma with variant histology: pathological features and clinical significance 51
Emerging Molecular Technologies in Genitourinary Tumors 50
Renal Cell Carcinoma: genomic landscape and clinical implications 50
Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators 50
Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis 50
Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy? 50
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? 50
Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC 49
Inguinal bladder hernia with lipomatosis of the bladder wall: A potential clinical pitfall for cancer 49
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 49
Molecular classification of bladder urothelial carcinoma using nanostring‐based gene expression analysis 49
Digital and computational transition in the pathology lab: when did it start? 49
Re: Theo van der Kwast, Fredrik Liedberg, Peter C. Black, et al. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.03.017: Focus on Our Personal Recollections and Observations 49
OUTCOMES OF DIFFERENT PATTERN OF SEMINAL VESICLE INVASION IN PATIENTS TREATED WITH RADICAL PROSTATECTOMY 48
Tumors of the Urinary System and Male Genital Organs: 2022 World Health Organization Classification and Multidisciplinarity 48
Myoid gonadal stromal tumours are characterised by recurrent chromosome-level copy number gains: molecular assessment of a multi-institutional series 48
Editorial: Emerging biomarkers in genitourinary tumors 48
Pathology without microscope: From a projection screen to a virtual slide 48
The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis 48
Towards a new WHO classification of renal cell tumor: What the clinician needs to know-a narrative review 48
Risk Classification of Bladder Cancer by Gene Expression and Molecular Subtype 48
Re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019;76:871 47
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 47
Exploring small extracellular vesicles for precision medicine in prostate cancer 47
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer 47
Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate 46
Re: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, Rodolfo Montironi, Daniel W. Lin, Mahul B. Amin. Updates in the Eighth Edition of the Tumor-node-metastasis Staging Classification for Urologic Cancers. Eur Urol 2018;73:560–9: Tumour, Node, and Metastasis Staging System for Urological Malignancies: Are We Ready for the Next Step? 46
Syndrome of inappropriate antidiuresis in prostate adenocarcinoma with neuroendocrine differentiation: a case report and literature review 46
Prostate cancer grading in 2018: Limitations, implementations, cribriform morphology, and biological markers 46
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 46
Lesson from the COVID-19 pandemic: pathologists need to build their confidence on working in a digital microscopy environment 46
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? 46
Totale 5.936
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.599
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.599
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023628 0 0 0 0 0 0 1 2 512 9 60 44
2023/2024411 25 9 17 10 36 24 10 22 88 112 29 29
2024/20253.489 74 226 38 51 63 162 97 106 341 449 584 1.298
2025/20266.069 502 740 1.030 924 807 621 603 288 256 298 0 0
Totale 10.597